# Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

Source: https://onco.cc/trials/nct06422936/  
OnCo record `nct06422936` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BO-112 in basal cell carcinoma, run by Highlight Therapeutics, active and no longer recruiting.

## Summary

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT06422936 by Highlight Therapeutics, with 60 participants enrolled, started 2024-05-27 and due to reach its primary completion in 2026-06. Interventions recorded: BO-112.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06422936
- Phase: 2
- Setting: SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma
- Sponsor: Highlight Therapeutics
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06422936: https://clinicaltrials.gov/study/NCT06422936

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06422936.json